obesity drug - Search News

Roche, obesity and Zealand

Reuters on MSN · 5h

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

CNBC on MSN · 7h

Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

BioPharma Dive · 2h

Roche broadens obesity drug plans with $1.65B Zealand deal

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.

Novo Nordisk, obesity and Weight-Loss Drug Trial Misses

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Business Insider · 1d

Novo Nordisk (NVO) Sinks after Weight-Loss Drug Trial Misses Expectations

Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug

2don MSN

Is the obesity drug market still a duopoly?

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

1don MSN

Who can get weight loss drugs on the NHS in Scotland?

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News ...

BioPharma Dive1d

Viking inks CordenPharma deal to boost obesity drug supply

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results